Cancer diagnosis and treatments- brief overview of the changing paradigm.

Similar documents
Advances in Chemotherapy for Non-Small Cell Lung Cancer

What You Need to Know About Lung Cancer Immunotherapy

IMMUNOTHERAPY FOR THE TREATMENT OF LUNG CANCER

New Oncology Drugs: Nadeem Ikhlaque, M.D Subtitle Would Go Here

CANCER IMMUNOTHERAPY Presented by John A Keech Jr DO MultiCare Regional Cancer Center

Cancer Prevention & Control in Adolescent & Young Adult Survivors

Policy. Medical Policy Manual Approved Revised: Do Not Implement until 6/30/2019. Nivolumab

Safety Immune Related Adverse Events (irae) Focus on NSCLC Aaron Hansen, BSc, MBBS, FRACP

Preparing for Your Immune Checkpoint Inhibitor (CPI) Treatment

Surveillance after Treatment of Malignancies. John M. Burke, M.D. March 2013

Oncology 101. Cancer Basics

Caring for a Patient with Colorectal Cancer. Objectives. Poll question. UNC Cancer Network Presented on 10/15/18. For Educational Use Only 1

IMMUNOTHERAPY FOR LUNG CANCER

Are we making progress? Marked reduction in operative morbidity and mortality

LYMPHOMA Joginder Singh, MD Medical Oncologist, Mercy Cancer Center

Survivorship in Cancer Care. Samantha Gray Medical Oncologist, SJRH April 20, 2018

Lipoplatin monotherapy for oncologists

Immunotherapy in Lung Cancer

IMMUNOTHERAPY FOR THE TREATMENT OF LUNG CANCER

Policy. Medical Policy Manual Approved Revised: Do Not Implement Until 3/2/19. Nivolumab (Intravenous)

Oncology General Principles L A U R I E S I M A R D B R E A S T S U R G I C A L O N C O L O G Y F E L L O W D E C E M B E R

Dr. Andres Wiernik. Lung Cancer

New paradigms for treating metastatic melanoma

UNDERSTANDING SQUAMOUS CELL LUNG CANCER

Johns Hopkins Clinical Update Webinar

Mind the Gap : Challenges in First-in- Man Evaluation of Immuno-Oncology Drugs

Establishing a Survivorship Program Within a Large Academic Medical Center

COLORECTAL CANCER 44

Karen Syrjala, PhD Co-Director, Survivorship Program

What is Cancer? Petra Ketterl, MD Medical Oncology and Functional Medicine

ESMO PRECEPTORSHIP IN IMMUNO-ONCOLOGY

Third Line and Beyond: Management of Refractory Colorectal Cancer

Chemotherapy for Urological Cancers

Adverse effects of Immunotherapy. Asha Nayak M.D

Index. Note: Page numbers of article titles are in boldface type.

U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Opdivo

Lung Cancer: Overview and Updates

GI Tumor Board 3/8/2018. Case #1 IDEA. Case #1 Question #1 What is the next step in management?

OPTIMAL MANAGEMENT OF IMMUNE- RELATED ADVERSE EVENTS ASSOCIATED WITH CHECKPOINT INHIBITORS

New Developments in Cancer Treatment. Ian Rabinowitz MD

Challenging Genitourinary Tumors: What s New in 2017

Indolent Lymphomas. Dr. Melissa Toupin The Ottawa Hospital

What is cancer? l Cancer is a group of several diseases caused by the abnormal growth of cells.

Immunotherapy. A Cancer Treatment Option

Gastric and Colon Cancer. Dr. Andres Wiernik 2017

Immune Checkpoint Inhibitors: A Guide for Cancer Patients

Patient Selection and Sequencing of Therapies in the New Melanoma Landscape

Immunotherapy and Lung Cancer

Keytruda. Keytruda (pembrolizumab) Description

ULTIMATE GBG 95 UC-0140/1606 BIG UnLock The IMmune cells ATtraction in ER+ breast cancer

Attachment #2 Overview of Follow-up

immunotherapy a guide for the patient

Immuno-Oncology: Essentials for Nurses in Cancer Care

II sessione. Immunoterapia oltre la prima linea. Alessandro Tuzi ASST Sette Laghi, Varese

Screening and Detection in Cancer Survivors. Jose W. Avitia, MD Oncology/Hematology

Overcoming Toxicities Associated with Novel Checkpoint Inhibitor Immunotherapy. Tara C. Gangadhar, MD Assistant Professor of Medicine ICI Boston 2016

guide to living with cancer Brought to you by Alliance Health.

Atezolizumab Non-small cell lung cancer

Martha Trout on 6/17/2012 at Pleasant Valley Cancer Center. Jane Plummer. Tom Plummer

Highlights from AACR 2015: The Emerging Potential of Immunotherapeutic Approaches in Non-Small Cell Lung Cancer

Targeted Medicine and Molecular Therapeutics. Angus McIntyre, M.D. Medical Oncologist, Addison Gilbert Hospital and Beverly Hospital October 6, 2009

Checkpoint Regulators Cancer Immunotherapy takes centre stage. Dr Oliver Klein Department of Medical Oncology 02 May 2015

Non-Small Cell Lung Cancer:

Keytruda. Keytruda (pembrolizumab) Description

Oncology 101. Marianne Davies, RN, APRN Yale Cancer Center September 2006

Medicinae Doctoris. One university. Many futures.

Keytruda. Keytruda (pembrolizumab) Description

COME HOME Innovative Oncology Business Solutions, Inc.

Innovations in Immunotherapy - Melanoma. Systemic Therapies October 27, 2018 Charles L. Bane, MD

Current and Future Treatment Options for Glioblastoma

Ovarian Cancer. Georgia McCann, MD. Division of Gynecologic Oncology

Immunotherapy for the Treatment of Melanoma. Marlana Orloff, MD Thomas Jefferson University Hospital

Immunotherapy in Colorectal cancer

New Developments in Cancer Treatment. Dulcinea Quintana, MD

Disclosure. Nothing to Disclose Will not be discussing off label use of any of the medications

Immunotherapy for NSCLC: Current State of the Art and Future Directions. H. Jack West, MD Swedish Cancer Institute Seattle, Washington, United States

SMALL CELL LUNG CANCER

Breast Cancer Treatment

Update on Melanoma Treatment. Tara C Mitchell, MD

Where do these cells come from?

immunotherapy What you need to know about... LUNG CANCER TREATMENTS

NCCN Non-Small Cell Lung Cancer V Meeting June 15, 2018

Professor Mark Bower Chelsea and Westminster Hospital, London

2016 Updates in Oncology & Malignant Hematology Brendan Curley, DO

For the Patient: USMAVNIV

SURVIVORSHIP WITH LYMPHOMA APRIL SHAMY MD,CM JEWISH GENERAL HOSPITAL MCGILL UNIVERSITY

Colon, or Colorectal, Cancer Information

Cancer in Women. Lung cancer. Breast cancer

Acute: Symptoms that start and worsen quickly but do not last over a long period of time.

A Brief Overview of Screening and Management of Colorectal Cancer

Updates in Cancer Genetics & Genomics

SAMPLE. Survivorship Care Plan for Lymphoma (Diffuse Large B-Cell) General Information. Care team

An Overview of Blood and Marrow Transplantation

Attached from the following page is the press release made by BMS for your information.

General Information, efficacy and safety data

For the Patient: ULUAVPMB

RAVE DATA ENTRY GUIDELINES S1400 & SUB-STUDIES. Protocol Ver. 1/8/18

Objectives. Briefly summarize the current state of colorectal cancer

Indiana University Hematology Oncology Fellows Research Interest

Transcription:

Cancer diagnosis and treatments- brief overview of the changing paradigm. Pranshu Bansal MD New Mexico Cancer Center

Identifying cancer in clinic Most common cancers are lung, breast, colon, prostate and cervical. Screening available for all these cancers Basic screening guidelines should be followed Other indicators include unexplained anemia, chronic fatigue, weight loss etc. Diagnosing any of the common cancers at an early stage leads to long survival.

Main treatment options for cancer Surgery Radiation therapy Systemic therapy 1) Chemotherapy 2) Targeted therapy 3) Immunotherapy

Fast evolving field

Chemotherapy- basics

Chemo settings Neoadjuvant- prior to surgery- goal is cancer cure Adjuvant- After surgery- goal is prevention of cancer recurrence Palliative- When cancer is widespread and goal is to prolong life and improve quality of life

Selecting chemotherapy based on efficacy and toxicity Cells of the bone marrow and GI tract are the most sensitive to the narrow therapeutic window Although some s/e like diarrhea, hair loss and increased risk of infection are common. There are specific side effects to each chemotherapy Adriamycin- cardiotoxicity (baseline ECHO) Vincristine, Oxaliplatin- Neuropathy (Prior H/O DM) Cisplatin- Kidney toxicity, ototoxicity (Age) Alimta- Allergic reaction (Patient education)

Chemotherapy- Administration Usually chemotherapy is administered in cycles which usually (Once every 2 or 3 weeks) Patients are seen in clinic prior to every chemo and toxicity assessment is performed Usually chemotherapy are given in combination of 2 or more drugs Combination chemo is usually continued for 4-6 months and after that a switch to single agent is made if the patient is responding.

Chemotherapy- activity and resistance Some cancers are more chemosenstive- colon cancer is treated with FOLFOX has a response rate of >50%, testicular cancers respond very well to cisplatin with >90% response rate However resistance to chemotherapy eventually develops and thus requires either a change in treatment plan to an alternative regimen Mechanism of resistance can include

Targeted therapy basics The first targeted therapy to receive FDA approval was tamoxifen in 1970 Targeted therapies work very well in certain cancers where the target is gene mutation that s driving the cancer growth Imatinib is a targeted therapy for CML which results in response in >70% patients for >5-7 years Lung cancer in non smokers can frequently have a driver mutation that can be targeted (>10 cancer drugs in lung cancer targeting genes have been approved)

Targeted therapy administration Mostly targeted therapies are oral pills, some can however be IV drugs given every 3 weeks They can be efficacious by themselves or may sometimes be combined with chemotherapy When combined with chemotherapy they allow the benefit of possibly increasing the response rate without adding a lot of toxicity

Targeted therapy side effects Skin toxicity is a common side effect with a lot of targeted agents (rashes, dryness) Others can have unique side effect profile based on the target VEGF inhibitors can cause HTN and bleeding BRAF inhibitors can increase risk of skin cancers

Cancer Immunotherapy In the News

Immunotherapy- basics There is a lot of hype in oncology over the potential of immunotherapy The basic premise is to make the body s own lymphocytes recognize the cancer cell as a foreign entity and try to kill it This can be achieved in myriad of ways and some FDA approved drugs include checkpoint inhibitors and CAR-T cells

Checkpoint inhibitors Pembrolizumab, nivolumab- PD-1 inhibtors Avelumab, Durvalumab- PD-L1 inhibitors

Immunotherapy- administration Usually given once every 2 or 3 weeks Continued till disease response Usually well tolerated

Immunotherapy- side effects Immune related adverse effects Colitis- diarrhea Pneumonitis- cough/sob Hypothyroidism Hypophysitis Adrenal insufficiency Fatigue

Post treatment surveillance Surveillance is guideline driven and is different for every cancer Colon cancer patients usually require follow up colonoscopy in 6 months to 1 year Lung cancer patients need follow up CT scans of chest Prostate cancer annual PSA check Testicular cancers every 3-6 month tumor marker check Breast cancer patients annual mammogram

Cancer survivors- common symptoms Fatigue Depression Anxiety Fertility counseling Neuropathy Genetic counseling